NeuroSense Therapeutics Ltd.
NRSN$27M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaHERZLIYA17 employees
Drugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Jun 30, 2026
17dMarket Overview
Stock performance and key metrics
NRSN News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
PrimeC
Alzheimer Disease
Fixed dose combination Ciprofloxacin/Celecoxib
Amyotrophic Lateral Sclerosis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
PrimeC | Phase 2 | Alzheimer Disease | - | - |
Fixed dose combination Ciprofloxacin/Celecoxib | Phase 2 | Amyotrophic Lateral Sclerosis | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply